Genomic effects of estradiol in Angioedema. Implications for contraception and hormonal menopause treatment;Contrôle génique par l'estradiol, application à l'angiœdème. Implications en contraception et traitement de ménopause

Revue Francaise d'Allergologie et d'Immunologie Clinique

Volumn 48, Issue 6, 2008, Pages 447-451

  Gompel, A ^a  

^a HÔTEL DIEU   (France)

Author keywords

Angioedema; Estrogen dependent inherited form of angioedema; Hereditary angioedema; Menopause

Indexed keywords

BLOOD CLOTTING FACTOR 12; BRADYKININ; COMPLEMENT COMPONENT C1; COMPLEMENT INHIBITOR; ESTRADIOL; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR BETA; GESTAGEN; KALLIKREIN; KININOGEN; TIBOLONE;

ANGIONEUROTIC EDEMA; CONTRACEPTION; DNA POLYMORPHISM; DNA SEQUENCE; GENETIC TRANSCRIPTION; HORMONAL THERAPY; HORMONE RECEPTOR INTERACTION; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; MENOPAUSAL SYNDROME; MENOPAUSE; PLEIOTROPY; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN METABOLISM; SHORT SURVEY; TARGET CELL; TRANSCRIPTION INITIATION;

EID: 53849145697     PISSN: 03357457     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.allerg.2008.02.008     Document Type: Short Survey

References (31)

1. Bork K., Barnstedt S.E., Koch P., and Traupe H. Hereditary angioedema with normal C1-inhibitor activity in women. Lancet 356 (2000) 213-217
2. Bork K., Gul D., Hardt J., and Dewald G. Hereditary angioedema with normal C1 inhibitor: clinical symptoms and course. Am J Med 120 (2007) 987-992
3. Edwards D.P. Regulation of signal transduction pathways by estrogen and progesterone. Annu Rev Physiol 67 (2005) 335-376
4. Zahedi K., Prada A.E., and Davis III A.E. Transcriptional regulation of the C1 inhibitor gene by gamma-interferon. J Biol Chem 269 (1994) 9669-9674
5. Cohen A.J., Laskin C., and Tarlo S. C1 esterase inhibitor in pregnancy. J Allergy Clin Immunol 90 (1992) 412-413
6. Halbmayer W.M., Hopmeier P., Mannhalter C., Heuss F., Leodolter S., Rubi K., et al. C1-esterase inhibitor in uncomplicated pregnancy and mild and moderate preeclampsia. Thromb Haemost 65 (1991) 134-138
7. Ogston D., Walker J., and Campbell D.M. C1 inactivator level in pregnancy. Thromb Res 23 (1981) 453-455
8. Laurell C.B., and Rannevik G. A comparison of plasma protein changes induced by danazol, pregnancy, and estrogens. J Clin Endocrinol Metab 49 (1979) 719-725
9. Gordon E.M., Ratnoff O.D., Saito H., Donaldson V.H., Pensky J., and Jones P.K. Rapid fibrinolysis, augmented Hageman factor (factor XII) titers, and decreased C1 esterase inhibitor titers in women taking oral contraceptives. J Lab Clin Med 96 (1980) 762-769
10. Falus A., Feher K.G., Walcz E., Brozik M., Füst G., Hidvegi T., et al. Hormonal regulation of complement biosynthesis in human cell lines-I. Androgens and gamma-interferon stimulate the biosynthesis and gene expression of C1 inhibitor in human cell lines U937 and HepG2. Mol Immunol 27 (1990) 191-195
11. Citarella F., Misiti S., Felici A., Aiuti A., La Porta C., and Fantoni A. The 5′ sequence of human factor XII gene contains transcription regulatory elements typical of liver specific, estrogen-modulated genes. Biochim Biophys Acta 1172 (1993) 197-199
12. Citarella F., Misiti S., Felici A., Farsetti A., Pontecorvi A., and Fantoni A. Estrogen induction and contact phase activation of human factor XII. Steroids 61 (1996) 270-276
13. Farsetti A., Misiti S., Citarella F., Felici A., Andreoli M., Fantoni A., et al. Molecular basis of estrogen regulation of Hageman factor XII gene expression. Endocrinology 136 (1995) 5076-5083
14. Citarella F., Ravon D.M., Pascucci B., Felici A., Fantoni A., and Hack C.E. Structure/function analysis of human factor XII using recombinant deletion mutants. Evidence for an additional region involved in the binding to negatively charged surfaces. Eur J Biochem 238 (1996) 240-249
15. Cichon S., Martin L., Hennies H.-C., Muller F., van Driessche K., Karpushova A., et al. Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. Am J Hum Genet 79 (2006) 1098-1104
16. Murray S.R., Chao J., Lin F.K., and Chao L. Kallikrein multigene families and the regulation of their expression. J Cardiovasc Pharmacol 15 Suppl. 6 (1990) S7-S16
17. Shaw J.L., and Diamandis E.P. Distribution of 15 human kallikreins in tissues and biological fluids. Clin Chem 53 (2007) 1423-1432
18. Madeddu P., Emanueli C., Song Q., Varoni M.V., Demontis M.P., Anania V., et al. Regulation of bradykinin B2-receptor expression by oestrogen. Br J Pharmacol 121 (1997) 1763-1769
19. Chen L.M., Chung P., Chao S., Chao L., and Chao J. Differential regulation of kininogen gene expression by estrogen and progesterone in vivo. Biochim Biophys Acta 1131 (1992) 145-151
20. Proudler A.J., Ahmed A.I., Crook D., Fogelman I., Rymer J.M., and Stevenson J.C. Hormone replacement therapy and serum angiotensin-converting-enzyme activity in postmenopausal women. Lancet 346 (1995) 89-90
21. Barton M., Cremer J., and Mugge A. 17Beta-estradiol acutely improves endothelium-dependent relaxation to bradykinin in isolated human coronary arteries. Eur J Pharmacol 362 (1998) 73-76
22. André F., Veysseyre-Balter C., Rousset H., Descos L., and André C. Exogenous oestrogen as an alternative to food allergy in the aetiology of angioneurotic oedema. Toxicology 185 (2003) 155-160
23. Gompel A., Kuttenn F., and Mauvais-Jarvis P. Contraception in the woman with lupus erythematosus. Ann Dermatol Venereol 115 (1988) 367-372
24. Gompel A. Contraceptions in women with contra-indication to estrogen-progestins. Rev Prat 45 (1995) 2431-2434
25. Gompel A., Pelissier C., Kuttenn F., and Mauvais-Jarvis P. Hormones and lupus. Rev Med Interne 6 (1985) 543-552
26. Pélissier C., Blacker C., Feinstein M.C., Cournot A., and Denis C. Antiovulatory action of chlormadinone acetate. Contracept Fertil Sex 22 (1994) 37-40
27. Pélissier C., Basdevant A., Conard J., Egloff M., Husson T., and Guyenne T.T. Progestogen contraception using chlormadinone acetate in women presenting high vascular risk. (A gynecoendocrine, metabolic and vascular study). Contracept Fertil Sex 15 (1987) 45-54
28. Gompel A., Carpentier S., Frances C., and Piette J.-C. Risk of venous thromboembolism and oral contraceptives. Lancet 359 (2002) 1348-1349
29. Jamin C., Intrator L., Laurent J., and Lagrue G. Cyproterone acetate is not effective in the prevention of hereditary angioneurotic edema. Presse Med 14 (1985) 1559-1560
30. Jamin C., Batallan A., and Madelenat P. Antigonadotropic effects of a 19-nor-progesterone derivative: the example of nomegestrol acetate. Gynecol Obstet Fertil 31 (2003) 70-81
31. Ott H.W., Mattle V., Hadziomerovic D., Licht P., Doinghaus K., Rubbert A., et al. Treatment of hereditary angioneurotic oedema (HANE) with tibolone. Clin Endocrinology (Oxf) 66 (2007) 180-184